↓ Skip to main content

Transporter-Mediated Interaction Between Platinum Drugs and Sorafenib at the Cellular Level

Overview of attention for article published in The AAPS Journal, November 2017
Altmetric Badge

Mentioned by

twitter
1 X user
facebook
1 Facebook page

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
5 Mendeley
Title
Transporter-Mediated Interaction Between Platinum Drugs and Sorafenib at the Cellular Level
Published in
The AAPS Journal, November 2017
DOI 10.1208/s12248-017-0169-2
Pubmed ID
Authors

Verena Schneider, Selim Chaib, Claudia Spanier, Mandy Knapp, Violeta Moscvin, Laura Scordovillo, Alessandra Ewertz, Ulrich Jaehde, Ganna V. Kalayda

Abstract

Combining the multikinase inhibitor sorafenib with the platinum-based chemotherapy of solid tumors was expected to improve treatment outcome. However, in many clinical trials, no benefit from sorafenib addition to the platinum-containing regimen could be demonstrated. Moreover, in some studies, decreased survival of ovarian cancer patients as well as non-small cell lung cancer patients with squamous cell histology was observed. The aim of this study was to investigate the cellular mechanisms of the pharmacological interaction between platinum drugs and sorafenib in different cancer cell lines. The interaction was characterized by combination index analysis, platinum accumulation and DNA platination were determined using flameless atomic absorption spectrometry, and protein expression was assessed with Western blot. In the sensitive A2780 ovarian carcinoma and H520 squamous cell lung carcinoma cell lines, sorafenib induced downregulation of Na+,K+-ATPase. In A2780 cells, the kinase inhibitor also decreased the expression of copper transporter 1 (CTR1). As a result, sorafenib treatment led to a diminished cellular accumulation of cisplatin and carboplatin and to a decrease in DNA platination in these cell lines. This was not the case in the cisplatin-resistant A2780cis ovarian carcinoma and H522 lung adenocarcinoma cell lines featuring lower basal expression of the above-mentioned transporters. In all cell lines studied, an antagonistic interaction between platinum drugs and sorafenib was found. Our results suggest that sorafenib impairs cisplatin and carboplatin uptake through downregulation of CTR1 and/or Na+,K+-ATPase resulting in reduction of DNA platination. This effect is not observed in cancer cells with defects in platinum accumulation.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 5 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 2 40%
Student > Bachelor 1 20%
Unknown 2 40%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 2 40%
Medicine and Dentistry 1 20%
Unknown 2 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 March 2018.
All research outputs
#17,932,482
of 23,025,074 outputs
Outputs from The AAPS Journal
#1,051
of 1,295 outputs
Outputs of similar age
#305,631
of 437,944 outputs
Outputs of similar age from The AAPS Journal
#15
of 27 outputs
Altmetric has tracked 23,025,074 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,295 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 14th percentile – i.e., 14% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,944 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.